Xencor (XNCR) Cantor Global Healthcare Conference 2025 summary

Strategic evolution and platform overview

• Focus on advancing differentiated molecules for severe diseases using XmAb protein engineering, expanding from oncology into autoimmune indications.

• Emphasis on creating bispecific antibodies and optimized monoclonal antibodies with long half-life and high potency.

• Strategic shift into immunology has resonated well due to unique competitive positioning.

XmAb819 bispecific T cell engager program

• XmAb819 targets ENPP3, highly expressed on renal cell carcinoma and other solid tumors, using a two-plus-one bispecific design.

• High tumor selectivity achieved by dual binding domains, activating T cells only in high antigen density environments.

• Dose escalation data to be presented at AACR-NCI-EORTC meeting in October, focusing on anti-tumor activity and safety.

• ENPP3 expression remains high across all therapy lines in treated patients.

• Program aims to address unmet needs in later-line clear cell renal cell carcinoma, with potential for significant impact.

TL1A and XmAb942 immunology pipeline

• TL1A identified as a promising target for best-in-class antibody development, with current focus on ulcerative colitis and potential in Crohn’s and other diseases.

• XmAb942, a long-acting TL1A antibody, is entering a phase 2b study (Zenith UC) with global rollout and plans for additional indications.

• Bispecific TL1A/IL-23 antibody planned for first-in-human studies in 2026, leveraging validated safety and potential synergy.

• Modeling and design aim for 99% inhibition in the gut, supporting every three-month dosing for maintenance.

• Ongoing evaluation of trial design and patient selection to optimize outcomes, learning from recent IBD studies.